Transcenta Holding Limited (06628.HK)価格

Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company, which engages in discovery, research, development, and manufacturing of differentiated antibody therapies in therapeutic areas with high unmet medical needs. The company is headquartered in Suzhou, Anhui and currently employs 171 full-time employees. The company went IPO on 2021-09-29. The firm's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm also provides contract development and manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.